Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCT Nuvectis Pharma, Inc.

Market Closed 08-14 16:00:00 EDT

18.96

-0.27

-1.40%

盘后18.96

+0.000.00%

19:34 EDT

High20.30	Low18.87	Vol106.66K
Open20.30	D1 Closing19.23	Amplitude7.46%
Mkt Cap617.75M	Tradable Cap402.58M	Total Shares32.58M
T/O2.04M	T/O Rate0.50%	Tradable Shares21.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCT","market":"US","secType":"STK","nameCN":"Nuvectis Pharma, Inc.","latestPrice":18.96,"timestamp":1786737600000,"preClose":19.23,"halted":0,"volume":106660,"hourTrading":{"tag":"盘后","latestPrice":18.96,"preClose":18.96,"latestTime":"19:34 EDT","volume":1316,"amount":24951.36,"timestamp":1786750444876,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.014040561622464877,"floatShares":21233168,"shares":32581500,"eps":-1.304535,"marketStatus":"Market Closed","change":-0.27,"latestTime":"08-14 16:00:00 EDT","open":20.3,"high":20.3,"low":18.865,"amount":2044182.0973,"amplitude":0.074623,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.304535,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"listingDate":1638334800000,"exchange":"NASDAQ","adjPreClose":19.23,"preHourTrading":{"tag":"盘前","latestPrice":19.46,"preClose":19.23,"latestTime":"09:29 EDT","volume":200,"amount":3892,"timestamp":1786714199999,"change":0.23,"changeRate":0.01196,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":18.96,"preClose":18.96,"latestTime":"19:34 EDT","volume":1316,"amount":24951.36,"timestamp":1786750444876,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7635008521018117,"impliedVol":0.7007,"impliedVolPercentile":0.2948},"requestUrl":"/m/hq/s/NVCT","defaultTab":"news","newsList":[{"id":"2657656904","title":"Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656904","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656904?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:30","pubTimestamp":1786033844,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. ($NVCT) announced an update on their ongoing clinical study. Nuvectis Pharma, Inc. is running a Phase 1 study called “A Phase...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nuvectis-nxp800-ovarian-cancer-trial-terminated-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nuvectis-nxp800-ovarian-cancer-trial-terminated-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4139","ISBC","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657527545","title":"Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657527545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657527545?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:30","pubTimestamp":1785958207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nuvectis-pharma-nvct-and-eyepoint-pharmaceuticals-eypt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nuvectis-pharma-nvct-and-eyepoint-pharmaceuticals-eypt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XLV","XBI","BK4585","LU0128526141.USD","LU0320765992.SGD","NVCT","LU0029874061.USD","LU0109394709.USD","LU0889565916.HKD","BK4581","BK4137","BK4007","EYPT","BK4139","HCSG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683935","title":"Nuvectis Pharma: Buy Rating Reiterated as Late-Stage Pipeline Expands and $39 Price Target Remains Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683935","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657683935?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:35","pubTimestamp":1785861331,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma and keeping the price target at $39.00. Joseph Pantginis h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nuvectis-pharma-buy-rating-reiterated-as-late-stage-pipeline-expands-and-39-price-target-remains-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nuvectis-pharma-buy-rating-reiterated-as-late-stage-pipeline-expands-and-39-price-target-remains-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656511045","title":"Nuvectis Pharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656511045","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656511045?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:35","pubTimestamp":1785850523,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings SummaryNuvectis Pharma IncNVCT.OQreported a quarterly adjusted loss of 30 cents per share for the quarter ended June 30, id","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555960","title":"Nuvectis Pharma Q2 FY26 Net Loss Widens to USD 7.02 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555960","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555960?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:08","pubTimestamp":1785845327,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Q2 FY26 net loss widens to USD 7.02 millionNuvectis Pharma posted a GAAP net loss of USD 7.02 million, widening from USD 6.33 million a year earlier.R&D expense rose to USD 4.68 millio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLbKy41f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0239","NVCT","BK0077","002653","BK0028","BK0188","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555582","title":"Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555582","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555582?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:03","pubTimestamp":1785845009,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is unchanged from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60903088/nuvectis-pharma-q2-eps-0-30-misses-0-26-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553754","title":"Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553754?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:00","pubTimestamp":1785844808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA76V6J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655652033","title":"Nuvectis Pharma Inc Expected to Post a Loss of 26 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2655652033","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655652033?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:02","pubTimestamp":1785499352,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc <NVCT.OQ> expected to post a loss of26cents a share - Earnings PreviewNuvectis Pharma IncNVCT.OQNVCT.Ois expected to  show no change in quarterly revenue when it reports  results o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL8N43X1OQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653354410","title":"Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653354410","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653354410?lang=en_us&edition=fundamental","pubTime":"2026-07-24 23:36","pubTimestamp":1784907412,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $30.00. Rahman cover...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-nuvectis-pharma-nvct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-nuvectis-pharma-nvct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653724055","title":"Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2653724055","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653724055?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:30","pubTimestamp":1784824232,"startTime":"0","endTime":"0","summary":"WSW, NY, July 23rd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China’s Na...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/nuvectis-nxp100-just-achieved-the-first-marketing-approval-ever-for-a-once-daily-oral-factor-b-inhibitor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/nuvectis-nxp100-just-achieved-the-first-marketing-approval-ever-for-a-once-daily-oral-factor-b-inhibitor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONEQ","QDTE","NQmain","QQQY","PSQ","IYW","QQQE","MNQmain","QQQJ","TQQQ","QQQ","QID","NVIW.SI",".IXIC","TECS","QQQM","TQQY","QQQA","GPIQ","BK4139","NDX","QLD","QYLG","SQQQ","FTEC","NVCT","JEPQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653721454","title":"Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2653721454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653721454?lang=en_us&edition=fundamental","pubTime":"2026-07-23 23:25","pubTimestamp":1784820328,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target remains the same with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pantginis-reiterates-buy-on-nuvectis-citing-ciprocopan-approval-and-pipeline-diversification-price-target-maintained-at-39-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pantginis-reiterates-buy-on-nuvectis-citing-ciprocopan-approval-and-pipeline-diversification-price-target-maintained-at-39-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653723504","title":"Nuvectis Pharma Says Paroxysmal Nocturnal Hemoglobinuria Drug Approved by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2653723504","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653723504?lang=en_us&edition=fundamental","pubTime":"2026-07-23 21:07","pubTimestamp":1784812063,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma  said Thursday that ciprocopan, also known as NXP100, has received marketing approval from the National Medicinal Products Administration of China for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria who had previously been untreated with Complement inhibitors.China-based Haisco developed the drug and handles its development, regulatory approvals, and commercialization in the country, while Nuvectis holds exclusive rights to develop and commercialize ciprocopan outside of Greater China, India, and certain Southeast Asian countries, Nuvectis said.The approval was based on a late-stage study by Haisco that demonstrated ciprocopan's superiority over eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria who had previously not been treated with Complement inhibitors, the statement said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653728798","title":"Nuvectis Corrects Title of Ciprocopan China Marketing Approval Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2653728798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653728798?lang=en_us&edition=fundamental","pubTime":"2026-07-23 21:01","pubTimestamp":1784811661,"startTime":"0","endTime":"0","summary":"Nuvectis corrects title of ciprocopan China marketing approval releaseNuvectis issued a correction to its release, changing only the title.Corrected title states ciprocopan (NXP100) won China marketin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL3xlSXb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","BCDF","SG9999014013.SGD","NVCT","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","SG9999014039.USD","BK4112","IE00BKPKM429.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653574758","title":"Nuvectis Pharma receives marketing approval in China for ciprocopan","url":"https://stock-news.laohu8.com/highlight/detail?id=2653574758","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653574758?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:45","pubTimestamp":1784807123,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NVCT) announced that ciprocopan, a once-daily oral complement Factor B inhibitor, received marketing approval from the National Me...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-receives-marketing-approval-in-china-for-ciprocopan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-receives-marketing-approval-in-china-for-ciprocopan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653742517","title":"Nuvectis Says China Regulator Approves Ciprocopan for Treatment-naive PNH Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2653742517","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653742517?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:32","pubTimestamp":1784806339,"startTime":"0","endTime":"0","summary":"Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patientsNuvectis partner Haisco secured China NMPA marketing clearance for ciprocopan (NXP100) in treatment-naive paroxysmal n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL7gXz26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","BK4139","BK0033","IE00BN0W2T93.GBP","NDAQ","IE00B64PRP62.GBP","BK0239","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","NVCT","BK0077","SG9999014013.SGD","SG9999014005.SGD","BK4112","BK4585","LU0314104364.USD","IE00BN0W2V16.EUR","LU2095319765.USD","BK0028","BK0188","002653","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","BCDF","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653742331","title":"Nuvectis Pharma - Ciprocopan (nxp100) Receives Marketing Approval in China for Treatment-naive Pnh Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2653742331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653742331?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:30","pubTimestamp":1784806200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA6R8QGV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975043","title":"Nuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975043?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:32","pubTimestamp":1783614746,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. ($NVCT) announced an update on their ongoing clinical study. The Phase 1b clinical study titled “A Phase 1b Clinical Study of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nuvectis-pharmas-nxp900-combo-trial-adds-fresh-momentum-to-nvct-in-egfr-lung-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nuvectis-pharmas-nxp900-combo-trial-adds-fresh-momentum-to-nvct-in-egfr-lung-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929000","title":"The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929000","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929000?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:00","pubTimestamp":1783598415,"startTime":"0","endTime":"0","summary":"WSW, NY, July 9th, 2026, FinanceWire In June, Nuvectis Pharma (NASDAQ:NVCT) signed a deal that took it from a single-drug oncology company to the o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/the-billion-dollar-pill-with-nxp100-nuvectis-pharma-just-staked-its-claim-in-the-new-biotech-gold-rush?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/the-billion-dollar-pill-with-nxp100-nuvectis-pharma-just-staked-its-claim-in-the-new-biotech-gold-rush?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIW.SI","QQQE","IYW","QQQA","ONEQ","NDX","XBI","PSQ","TECS","NQmain","JEPQ","FTEC","QLD","BK4585","QQQY","MNQmain","QQQJ","BK4139","QDTE","TQQQ","BK4588","SQQQ",".IXIC","QYLG","QID","QQQ","GPIQ","NVCT","TQQY","QQQM","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649640686","title":"Nuvectis Pharma is Maintained at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640686","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649640686?lang=en_us&edition=fundamental","pubTime":"2026-07-06 17:29","pubTimestamp":1783330140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCT/analyst-ratings(END) Dow Jones NewswiresJuly 06, 2026 05:29 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649140846","title":"Nuvectis Pharma price target raised to $33 from $20 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649140846","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649140846?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:00","pubTimestamp":1783299606,"startTime":"0","endTime":"0","summary":"Roth Capital raised the firm’s price target on Nuvectis Pharma (NVCT) to $33 from $20 and keeps a Buy rating on the shares. The company “significan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-price-target-raised-to-33-from-20-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-price-target-raised-to-33-from-20-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvectis.com","stockEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":-0.0322},{"period":"3month","weight":0.7174},{"period":"6month","weight":1.1644},{"period":"1year","weight":1.9487},{"period":"ytd","weight":1.5113}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.130119},{"month":2,"riseRate":0.75,"avgChangeRate":0.147062},{"month":3,"riseRate":0.6,"avgChangeRate":0.077847},{"month":4,"riseRate":0.8,"avgChangeRate":0.055849},{"month":5,"riseRate":0.8,"avgChangeRate":0.192364},{"month":6,"riseRate":0.2,"avgChangeRate":0.054549},{"month":7,"riseRate":0.4,"avgChangeRate":-0.045885},{"month":8,"riseRate":0.4,"avgChangeRate":-0.028281},{"month":9,"riseRate":0,"avgChangeRate":-0.100626},{"month":10,"riseRate":0.5,"avgChangeRate":-0.011793},{"month":11,"riseRate":0.25,"avgChangeRate":-0.090389},{"month":12,"riseRate":0.75,"avgChangeRate":0.071233}],"exchange":"NASDAQ","name":"Nuvectis Pharma, Inc.","nameEN":"Nuvectis Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvectis Pharma, Inc.,NVCT,Nuvectis Pharma, Inc.股票,Nuvectis Pharma, Inc.股票老虎,Nuvectis Pharma, Inc.股票老虎国际,Nuvectis Pharma, Inc.行情,Nuvectis Pharma, Inc.股票行情,Nuvectis Pharma, Inc.股价,Nuvectis Pharma, Inc.股市,Nuvectis Pharma, Inc.股票价格,Nuvectis Pharma, Inc.股票交易,Nuvectis Pharma, Inc.股票购买,Nuvectis Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction